Skip to content

Study · Not a test of the peptide alone · 2025

12 results

Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment.

Yu F, Chen Y, Ouyang S, Tong B, Jiang Z, Wang J, Ding B, Mao K, Wu W, Xu H

Journal of controlled release : official journal of the Controlled Release Society5 Sept 2025

PMID40915363 (opens in a new tab)DOI10.1016/j.jconrel.2025.114205 (opens in a new tab)PepBankPUB-40915363
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Larazotide.

  1. 01AnimalNot a test of Larazotide aloneAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced colitis, HSMP-LA reduced disease activity.

    In plain wordsIn mice with colitis, HSMP-LA reduced disease activity.

    Peptide
    Larazotide
    Outcome
    DecreaseDisease activity
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    In DSS-induced colitis mice, HSMP-LA significantly reduced disease activity, suppressed pro-inflammatory cytokines and upregulated anti-inflammatory IL-10.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  2. 02AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In mice with DSS-induced colitis, HSMP-LA suppressed pro-inflammatory cytokines.

    In plain wordsIn mice with colitis, HSMP-LA reduced pro-inflammatory cytokines.

    Peptide
    Larazotide
    Outcome
    DecreasePro-inflammatory cytokines
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    In DSS-induced colitis mice, HSMP-LA significantly reduced disease activity, suppressed pro-inflammatory cytokines and upregulated anti-inflammatory IL-10.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  3. 03AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In mice with DSS-induced colitis, HSMP-LA increased anti-inflammatory IL-10.

    In plain wordsIn mice with colitis, HSMP-LA increased IL-10.

    Peptide
    Larazotide
    Outcome
    IncreaseIL-10
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    In DSS-induced colitis mice, HSMP-LA significantly reduced disease activity, suppressed pro-inflammatory cytokines and upregulated anti-inflammatory IL-10.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  4. 04AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In mice with colitis, HSMP-LA repaired tight junctions involving ZO-1, occluding and claudin-5.

    In plain wordsIn mice with colitis, HSMP-LA repaired tight junctions.

    Peptide
    Larazotide
    Outcome
    IncreaseTight junction repair
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    It repaired tight junctions (ZO-1, occluding and claudin-5), restored mucus production (MUC2), and rebalanced gut microbiota.
    1 context sentence
    Summary · context
    In DSS-induced colitis mice, HSMP-LA significantly reduced disease activity, suppressed pro-inflammatory cytokines and upregulated anti-inflammatory IL-10.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  5. 05AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In mice with colitis, HSMP-LA restored mucus production involving MUC2.

    In plain wordsIn mice with colitis, HSMP-LA restored mucus production.

    Peptide
    Larazotide
    Outcome
    IncreaseMucus production
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    It repaired tight junctions (ZO-1, occluding and claudin-5), restored mucus production (MUC2), and rebalanced gut microbiota.
    1 context sentence
    Summary · context
    In DSS-induced colitis mice, HSMP-LA significantly reduced disease activity, suppressed pro-inflammatory cytokines and upregulated anti-inflammatory IL-10.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  6. 06AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In mice with colitis, HSMP-LA rebalanced gut microbiota.

    In plain wordsIn mice with colitis, HSMP-LA rebalanced gut microbes.

    Peptide
    Larazotide
    Outcome
    Not applicableGut microbiota
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    It repaired tight junctions (ZO-1, occluding and claudin-5), restored mucus production (MUC2), and rebalanced gut microbiota.
    1 context sentence
    Summary · context
    In DSS-induced colitis mice, HSMP-LA significantly reduced disease activity, suppressed pro-inflammatory cytokines and upregulated anti-inflammatory IL-10.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  7. 07LabNot a test of Larazotide aloneIn vitro (cells)Activity measurement

    HSMP-LA showed broad-spectrum antimicrobial activity.

    In plain wordsIn lab tests, HSMP-LA showed broad-spectrum antimicrobial activity.

    Peptide
    Larazotide
    Outcome
    Not applicableAntimicrobial activity
    Study

    n: not reported in source

    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Besides, HSMP-LA showed the broad-spectrum antimicrobial activity,

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  8. 08LabNot a test of Larazotide aloneIn vitro (cells)Mechanism

    In LPS-injured Caco-2 cells, sustained-release LA in HSMP-LA inhibited zonulin-mediated tight junction disruption via MLCK/p-MLC signals.

    In plain wordsIn cells, sustained-release larazotide in HSMP-LA inhibited zonulin-mediated tight junction disruption.

    Peptide
    Larazotide
    Outcome
    DecreaseTight junction disruption
    Study

    n: not reported in source

    LPS-injured Caco-2 cells
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    while its sustained-release LA selectively inhibited zonulin-mediated tight junction disruption via combating MLCK/p-MLC signals, restoring epithelial integrity in LPS-injured Caco-2 cells.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  9. 09LabNot a test of Larazotide aloneIn vitro (cells)Mechanism

    In LPS-injured Caco-2 cells, HSMP-LA restored epithelial integrity.

    In plain wordsIn cells, HSMP-LA restored epithelial integrity after LPS injury.

    Peptide
    Larazotide
    Outcome
    IncreaseEpithelial integrity
    Study

    n: not reported in source

    LPS-injured Caco-2 cells
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    while its sustained-release LA selectively inhibited zonulin-mediated tight junction disruption via combating MLCK/p-MLC signals, restoring epithelial integrity in LPS-injured Caco-2 cells.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  10. 10LabNot a test of Larazotide aloneIn vitro (cell-free)Other

    HSMP-LA exhibited robust muco-adhesion in material tests.

    In plain wordsIn lab tests, HSMP-LA showed robust adhesion to mucus.

    Peptide
    Larazotide
    Outcome
    Not applicableMuco-adhesion
    Study

    n: not reported in source

    HSMP-LA hydrogel
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    HSMP-LA exhibited robust muco-adhesion, the prolonged retention, and sustained-release profile of LA, effectively shielding the epithelium from luminal pathogens and toxins.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  11. 11LabNot a test of Larazotide aloneIn vitro (cell-free)Pharmacokinetics

    HSMP-LA exhibited prolonged retention.

    In plain wordsIn lab tests, HSMP-LA showed prolonged retention.

    Peptide
    Larazotide
    Outcome
    IncreaseRetention
    Study

    n: not reported in source

    HSMP-LA hydrogel
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    HSMP-LA exhibited robust muco-adhesion, the prolonged retention, and sustained-release profile of LA, effectively shielding the epithelium from luminal pathogens and toxins.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  12. 12LabNot a test of Larazotide aloneIn vitro (cell-free)Pharmacokinetics

    HSMP-LA exhibited sustained release of larazotide.

    In plain wordsIn lab tests, HSMP-LA released larazotide over a sustained period.

    Peptide
    Larazotide
    Outcome
    Not applicableSustained release
    Study

    n: not reported in source

    HSMP-LA hydrogel
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    HSMP-LA exhibited robust muco-adhesion, the prolonged retention, and sustained-release profile of LA, effectively shielding the epithelium from luminal pathogens and toxins.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.